BREAST CANCER IN WOMAN YOUNGER THAN 35 YEARS
Session type: Poster / e-Poster / Silent Theatre session
Theme: Diagnosis and therapy
Our aim was to report the epidemiological and clinical characteristics of breast cancer in young women and to evaluate the therapeutic Results in Radiotherapy Oncology department of Blida
We report the Results of a retrospective study including 64 patients less than 35 years old treated for breast cancer between January 2010 and December 2014 in our department
The median age of our pts is 29.6 years (range 23-35). 54% of pts have family history of malignancy (breast cancer, colorectal cancer and others). 5 pts were diagnosed with metastatic disease. The BI-RADS 5 was reported in 32.8% cases at diagnosis. 32% pts presented with grade 3 histology, Hormone receptors were positive in 42% pts, HER2 pos 21.8%, TNC 9%. 68.7% of all pts underwent a radical surgical treatment. Chemotherapy was given neoadjuvant for 12.5% and 56.5% pts received adjuvant chemotherapy.27 pts received hormonotherapy. After a median follow-up of 5 years, the overall survival was 35 months, the free disease survival was 36.3 months and progression free survival was 11.3 months
Breast cancer in young women is associated with adverse pathological factors, including high grade tumors, hormone receptor negativity, and HER2 over expression, which requires more aggressive treatments and the need for closer follow-up.